Journal of Diabetes and Its Complications
Volume 24, Issue 5 , Pages 306-312 , September 2010

Transforming growth factor beta 1 as a biomarker of diabetic peripheral neuropathy: cross-sectional study

  • Juan Ybarra

      Affiliations

    • Instituto de Cardiología Avanzada (ICAMED), Centro Medico Teknon, Barcelona, Spain
    • Corresponding Author InformationCorresponding author. Instituto de Cardiología Avanzada, Centro Medico Teknon, C/ Vilana 12, 08017-Barcelona, Spain. Tel.: +34 93 2906459; fax: +34 93 2906458.
    • ,
  • Josep M. Pou

      Affiliations

    • Division of Endocrinology, Hospital de la Sta. Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain
    • ,
  • June Hart Romeo

      Affiliations

    • Baldwin-Wallace College, Division of Health, Berea, OH, USA
    • ,
  • Javier Merce

      Affiliations

    • Department of Biochemistry, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Spain
    • ,
  • Jeroni Jurado

      Affiliations

    • Primary Care Center, Catalan Health Institute, Olot, Girona, Spain

Received 6 April 2009 ,Revised 6 July 2009 ,Accepted 31 July 2009.

References 

  1. Agrawal RP, Sharma P, Pal M, Kochar A, Kochar DK. Magnitude of dyslipedemia and its association with micro and macro vascular complications in type 2 diabetes: A hospital based study from Bikaner (Northwest India). Diabetes Research and Clinical Practice. 2006;73:211–214
  2. Anjaneyulu M, Berent-Spillson A, Inoue T, Choi J, Cherian K, Russell JW. Transforming growth factor-beta induces cellular injury in experimental diabetic neuropathy. Experimental Neurology. 2008;211:469–479
  3. Benbow SJ, Wallymahmed ME, Macfarlane IA. Diabetic peripheral neuropathy and quality of life. Quarterly Journal of Medicine. 1998;91:733–737
  4. Benjafield AV, Glenn CL, Wang XL, Colagiuri S, Morris BJ. TNFRSF1B in genetic predisposition to clinical neuropathy and effect on HDL cholesterol and glycosylated hemoglobin in type 2 diabetes. Diabetes Care. 2001;24:753–757
  5. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor β in human disease. New England Journal of Medicine. 2000;342:1350–1358
  6. Boulton AJ, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. Diabetes Care. 2004;27:1458–1486
  7. Boulton AJM, Vileikyte L, Ragnarson-Tennvall G, Apelqvist J. The global burden of diabetic foot disease. Review Lancet. 2005;366:1719–1724
  8. Chantry D, Turner M, Abney E, Feldmann M. Modulation of cytokine production by transforming growth factor-beta. Journal of Immunology. 1989;142:429–435
  9. Cameron NE, Cotter MA. Pro-inflammatory mechanisms in diabetic neuropathy: Focus on the nuclear factor kappa B pathway. Current Drug Targets. 2008;9:60–67
  10. Delarue J, Maingourd C, Couet C, Vidal S, Bagros P, Lamisse F. Effects of oral glucose on intermediary metabolism in continuous ambulatory peritoneal dialysis patients versus healthy subjects. Peritoneal Dialysis International. 1998;18:505–511
  11. Dyck PJ, Kratz KM, Lehman KA, Karnes JL, Melton LJ, O'Brien PC, et al. The Rochester Diabetic Neuropathy Study: Design, criteria for types of neuropathy, selection bias, and reproducibility of neuropathic tests. Neurology. 1991;41:799–807
  12. Fukumoto H, Naito Z, Asano G, Aramaki T. Immunohistochemical and morphometric evaluations of coronary atherosclerotic plaques associated with myocardial infarction and diabetes mellitus. Journal of Atherosclerosis and Thrombosis. 1998;5:29–35
  13. Gerstein HC, Mann JF, Yi Q. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and non diabetic individuals. Journal of the American Medical Association. 2001;286:421–426
  14. Gruden G, Bruno G, Chaturvedi N, Burt D, Schalkwijk C, Pinach S, et al. Serum heat shock protein 27 and diabetes complications in the EURODIAB prospective complications study: A novel circulating marker for diabetic neuropathy. Diabetes. 2008;57(7):1966–1970
  15. Hadi HA, Suwaidi JA. Endothelial dysfunction in diabetes mellitus. Vascular Health Risk Management. 2007;3:853–876
  16. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality for coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New England Journal of Medicine. 1998;339:229–234
  17. Hong SY, Yang DH. Insulin levels and fibrinolytic activity in patients with end-stage renal disease. Nephron. 1994;68:329–333
  18. Iwasaki T, Togashi Y, Terauchi Y. Significant association of serum albumin with severity of retinopathy and neuropathy, in addition to that of nephropathy, in Japanese type 2 diabetic patients. Endocrine Journal. 2008;55(2):311–316
  19. Jiang X, Kanai H, Shigehara T, Maezawa A, Yano S, Naruse T. Metabolism of transforming growth factor-beta in patients receiving haemodialysis specially those with renal osteodystrophy. Renal Failure. 1988;20:135–145
  20. Jurado J, Caula J, Pou JM. Selection of risk and diagnosis in DPN. Validation of method of new systems. Atencion Primaria. 2006;38:116–121
  21. Jurado J, Ybarra J, Ferrandiz M, Comerma L, Pou JM. Is the aminoterminal pro-brain natriuretic peptide (NT-proBNP) a marker for DPN?. Diabetes Care. 2007;e86:30
  22. Jurado J, Ybarra J, Romeo JH, Pou J. Clinical screening and diagnosis of diabetic polyneuropathy: The North Catalonia Diabetes Study. European Journal of Clinical Investigation. 2009;39(3):183–189
  23. Krag S, Osterby R, Chai Q, Nielsen CB, Hermans C, Wogensen L. TGFβ1.induced glomerular disorders is associated with impaired concentrating ability mimicking primary glomerular disease with renal failure in men. Laboratory Investigation. 2000;80:1855–1958
  24. Mi Q, Rivière B, Clermont G, Steed DL, Vodovotz Y. Agent-based model of inflammation and wound healing: Insights into diabetic foot ulcer pathology and the role of transforming growth factor-beta1. Wound Repair and Regeneration. 2007;15:671–682
  25. Navarro JF, Mora C. Diabetes, inflammation, proinflammatory cytokines, and diabetic nephropathy. Scientific World Journal. 2006;6:908–917
  26. Nikol S, Isner JM, Pickering JG, Kearney M, Leclerc G, Weir L. Expression of transforming growth factor-beta 1 is increased in human vascular restenosis lesions. Journal of Clinical Investigation. 1992;90:1582–1592
  27. Partanen J, Niskanen L, Lehtinen J, Mervaala E, Siitonen O, Uusitupa M. Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. New England Journal of Medicine. 1995;333:89–94
  28. Pedersen O, Gaede P. Intensified multifactorial intervention and cardiovascular outcome in type 2 diabetes: The Steno-2 study. Metabolism. 2003;52:19–23
  29. Quattrini C, Tavakoli M, Jeziorska M, Kallinikos P, Tesfaye S, Finnigan J, et al. Surrogate markers of small fiber damage in human diabetic neuropathy. Diabetes. 2007;56(8):2148–2154
  30. Reeves WP, Androly TE. Transforming growth factor a contributes to progressive diabetic nephropathy. Proceedings of the National Academy of Sciences of the United States of America. 2000;97:7667–7669
  31. Roberts RA, Michel C, Coyle B, Freathy C, Cain K, Boitier E. Regulation of apoptosis by peroxisome proliferators. Toxicology Letters. 2004;149:37–41
  32. Rubino A, Rousculp MD, Davis K, Wang J, Bastyr EJ, Tesfaye S. Diagnosis of diabetic peripheral neuropathy among patients with type 1 and type 2 diabetes in France, Italy, Spain, and the United Kingdom. Primary Care Diabetes. 2007;1(3):129–134
  33. Sandhu HS, Butt AN, Powrie J, Swaminathan R. Measurement of circulating neuron-specific enolase mRNA in diabetes mellitus. Annals of the New York Academy of Sciences. 2008;1137:258–263
  34. Schneider CA. Improving macrovascular outcomes in type 2 diabetes: Outcome studies in cardiovascular risk and metabolic control. Current Medical Research and Opinion. 2006;22(Suppl. 2):S15–S26
  35. Shlipak MG, Ix JH, Bibbins-Domingo K, Lin F, Whooley MA. Biomarkers to predict recurrent cardiovascular disease: The Heart and Soul Study. American Journal of Medicine. 2008;121:50–57
  36. Smith AG, Russell J, Feldman EL, Goldstein J, Peltier A, Smith S, et al. Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care. 2006;29:1294–1299
  37. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434–444
  38. Tesfaye S, Chaturvedi N, Eaton SE, Ward JD, Manes C, Ionescu-Tirgoviste C, et al. Vascular risk factors and diabetic neuropathy. New England Journal of Medicine. 2005;352:341–350
  39. Tsuzura S, Ikeda Y, Suehiro T, Ota K, Osaki F, Arii K, et al. Correlation of plasma oxidized low-density lipoprotein levels to vascular complications and human serum paraoxonase in patients with type 2 diabetes. Metabolism. 2004;53:297–302
  40. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS:23). British Medical Journal. 1998;316:823–828
  41. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care. 2003;26:1553–1579

☆ Funding: Instituto de Salud Carlos III, FIS PI040181-PI070340, Plan Nacional I+D+I 2004-2007 y Fondos FEDER.

PII: S1056-8727(09)00091-9

doi: 10.1016/j.jdiacomp.2009.07.007

Journal of Diabetes and Its Complications
Volume 24, Issue 5 , Pages 306-312 , September 2010

Article Tools

* Image Usage & Resolution